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When chronic kidney disease (CKD) progresses to end-
stage renal disease (ESRD), the risk of cardiovascular 
mortality   increases  exponentially  [1]  and  occur  at  a  
 
much younger age [2]. This suggests that CKD could be 
used as a clinical model to study premature vascular 
ageing [3, 4]. Premature arteriosclerosis, i.e. medial 
vascular calcification (VC), is a distinct feature in CKD 
that predicts poor outcome [5]. Osteogenic factors, such 




























senescence and osteogenic  transformation. This has proven  intractable  to modelling  appropriately  in model
organisms.  We  have  therefore  investigated  this  directly  in  man,  using  for  the  first  time  validated  cellular
biomarkers of ageing  (CDKN2A/p16INK4a, SA‐β‐Gal)  in arterial biopsies  from 61 CKD patients undergoing  living
donor  renal  transplantation.  We  demonstrate  that  in  the  uremic  milieu,  increased  arterial  expression  of
CDKN2A/p16INK4a  associated with  vascular  progeria  in  CKD,  independently  of  chronological  age.  The  arterial
expression  of  CDKN2A/p16INK4a  was  significantly  higher  in  patients  with  coronary  calcification  (p=0.01)  and








www.aging‐us.com  2  AGING (Albany NY) 
as matrix Gla protein (MGP) and runt-related 
transcription factor 2 (RUNX2), are part of the 
calcification process. MGP is an important endogenous 
inhibitor of extracellular calcification expressed by 
vascular smooth muscle cells (VSMCs) [6, 7], while 
RUNX2 has emerged as a key factor in the osteogenic 
transformation of VSMC in response to high phosphate 
and oxidative stress [8, 9]. Uremic arteriosclerosis may 
in part be caused by increased vascular apoptosis [10, 
11].  
 
Studies have associated single nucleotide 
polymorphisms on chromosome 9p21 close to the 
cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) 
with risk for cardiovascular disease (CVD) in the 
general population [12-16]. As the proteins derived 
from CDKN2A/B are functionally involved in 
maintaining cells in a state of growth arrest, and cellular 
senescence increases with age, expression of CDKN2A 
increase as a function of increasing cellular stress and 
organismal ageing [17, 18]. Indeed, CDKN2A gene 


































a biomarker of biological age [19, 20]. Thus, elevated 
CDKN2A expression correlates with increased 
biological ageing as well as increased frequency of a 
frail phenotype [21].  
 
Since the expression of the CDKN2A/B locus has not 
been investigated in uremic tissue we investigated 
arterial and muscle CDKN2A/B expression in ESRD. 
We tested if the expression of the CDKN2A/B complex 
correlated to chronological age, degree of VC 
(estimated by histological examination of arteries, semi-
automated quantification and CT scans of the coronary 
arteries) and clinical CVD. We also related degree of 
VC to the number of p16INK4a and senescence associated 




Demography, biochemical data and arterial expression 
of CDKN2A/p16INK4a, CDKN2B/p15INK4a, RUNX2 and 
MGP in the different groups of VC (none, mild, 




































without  cardiovascular  disease  (A)  and  coronary  artery  calcification  (CAC)  score  0  vs.  >0  (B).
Cardiovascular disease was defined on clinical grounds. Coronary artery calcification score were
obtained through CT heart (n=47). CDKN2A=cyclin‐dependent kinase 2A. RQ=relative quantity.  
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differences (p=0.15) in the number of no/former/present 
smokers were found in the calcification groups (no VC; 
8/1/0, mild VC; 16/14/0, moderate VC; 7/7/0, severe 
VC; 3/1/0). Moreover, no difference (p=0.39) in 
physical activity (graded as regular, normal activity and 
disabled) was reported in the calcification groups (no 
VC; 2/6/1, mild VC; 18/13/1, moderate VC; 6/7/2, 
severe VC; 1/2/1). The arterial expression of 
CDKN2B/p15INK4a did not show any significant 
correlations with age, biomarkers of bone, inflammation 
and oxidative stress as well as extent of VC, coronary 
artery calcification (CAC) score or CVD. In contrast, 
the arterial CDKN2A/p16INK4a expression was 
significantly higher (Fig. 1) in patients with CVD 
compared to patients without CVD (median relative 
expression quantity 2.12 vs. 1.00, p=0.004), even after 
correction for age in multivariate analysis (p=0.01). 
Patients with CVD (632; IQR 79-1702) had 
significantly (p=0.0008) higher median CAC score than 
patients without clinical signs of CVD (0; IQR 0-64). 
 
The arterial expression of CDKN2A/p16INK4a correlated 
(Rho=0.34; p=0.006) with chronological age (Suppl. 
Fig. 2). Patients with CAC-score >0 had significantly 
higher (median relative expression quantity 1.32 vs. 
0.83 RQ; p=0.01) arterial expression of 
CDKN2A/p16INK4a than patients with CAC score 0 (Fig. 
1), but not after correction for age (p=0.12). The 
correlation between CDKN2A/p16INK4a and media 


























nificant in univariate analysis (Suppl. Fig. 3) but 
reached statistical significance (p=0.0003) after 
multivariate correction for chronological age. The 
arterial expression of CDKN2A/p16INK4a correlated with 
CAC score (Rho=0.41; p=0.004), IL-8 (Rho=0.31; 
p=0.016), IGF-1 (Rho=-0.30; p=0.02), testosterone 
(males only) (Rho=-0.50; p=0.001), Mid-fragments 
(MID)-osteocalcin (OC) (Rho=-0.52; p<0.0001), 
inactive GLU-type (GLU)-OC (Rho=-0.54; p<0.0001) 
and active GLA-type (GLA-OC) (Rho=-0.47; 
p=0.0004). The correlations between CDKN2A/p16INK4a 
and GLA-OC and CAC score are depicted in Figure 2. 
Median N-MID OC (27.0 vs. 115.4 ng/ml; p=0.013), 
GLU-OC (3.1 vs 34.4 ng/ml; p=0.02) and GLA-OC 
(13.3 vs. 45.5 ng/ml; p=0.014) were significantly lower 
in patients with CVD. 
 
As shown in Figure 3, arteries with severe medial VC 
exhibited significantly higher vascular expression of 
RUNX2 (p=0.0036), MGP (p=0.0002) and 
CDKN2A/p16INK4a (p=0.011). The arterial expression of 
CDKN2A/p16INK4a was significantly correlated to the 
expression of MGP (Rho=0.31; p=0.02), but not 
RUNX2 (Rho=0.21; p=0.16). The degree of media 
calcification (%) correlated to total CAC score 
(Rho=0.59; p<0.0001) and MGP expression (Rho=0.38; 
p=0.008), but not to RUNX2 expression (Rho=0.14). 
Total CAC score correlated to arterial MGP expression 




























Figure 2.  Correlations  between  the  arterial  expression  of  CDKN2A/p16INK4a  and  circulating  levels  of
carboxylated  (GLA) active osteocalcin  (A) and coronary artery calcification by CT heart  (B). CDKN2A =
cyclin‐dependent kinase 2A. RQ = relative quantity. HU = Hounsfield units. The exclusion of one patient
on warfarin did not affect the correlation between CDKN2A/p16INK4a and GLA‐OC (Rho=‐0.51; p=0.001). 



















































































































Demography Total (n=61) No VC (n=9) Mild VC (n=32) Moderate VC (n=16) Severe VC (n=4) P-value 
Age, years 45 (33-52) 28 (24-30) 44 (36-51) 49 (40-56) 53 (46-60) p<0.0001 
Males, n  42 5 20 13 4 p=0.1371 a
Cardiovascular disease, n 5 0 1 2 2 p=0.0464 a
Vintage, years 0.3 (0-1.1) 0.7 (0-1.0) 0.3 (0-1.0) 0.6 (0-1.2) 1.4 (0.3-2.0) p=0.8156 
Body mass index, kg/m2 23.8 (21.8-26.3) 21.0 (19.8-25.7) 23.5 (21.7-26.2) 24.8 (22.6-26.7) 23.2 (22.3-26.8) p=0.5453 
Metabolism             
Creatinine, µmol/L 739 (577-907) 760 (519-1146) 761 (592- 986) 800 (598-906) 914 (806-933) p=0.9366 
Cholesterol, mmol/L 4.6 (3.9-5.3) 4.4 (3.9-4.8) 4.4 (3.8-5.1) 5.1 (4.3-6.0) 4.7 (3.8-7.2) p=0.0853 
Triglyceride, mmol/L 1.2 (0.9-1.7) 1.0 (0.7-1.5) 1.1 (0.9-1.5) 1.4 (1.1-1.8) 1.4 (1.1-2.9) p=0.2950 
HDL-cholesterol, mmol/L 1.4 (1.1-1.6) 1.6 (1.3-1.9) 1.4 (1.1-1.6) 1.3 (1.0-1.5) 1.2 (1.1-2.3) p=0.4383 
IGF-1, ng/ml b 255 (175-289) 283 (261-326) 251 (183-291) 233 (175-282) 168 (147-370) p=0.5116 
Testosterone, mmol/L c 12.3 (8.7-15.7) 11.2 (6.5-28.6) 13.1 (9.2-15.8) 11.0 (7.5-15.5) 10.7 (7.2-18.7) p=0.6819 
Inflammation & oxidative             
stress             
hsCRP, mg/L 0.9 (0.5-2.5) 0.6 (0.4-1.6) 1.3 (0.5-3.0) 0.8 (0.5-1.5) 2.0 (0.5-9.4) p=0.8237 
IL-6, pg/mL 0.9 (0.5-1.8) 1.0 (0.3-1.8) 0.9 (0.6-2.1) 0.6 (0.3-1.4) 1.7 (1.4-16.5) p=0.0480 
IL-8, pg/mL 5.3 (3.5-7.9) 5.9 (2.3-8.5) 5.4 (3.6-8.3) 4.4 (3.1-7.7) 7.4 (4.8-11.3) p=0.4705 
TNF, pg/mL 10.7 (9.0-13.1) 9.7 (8.0-14.7) 10.8 (9.3-12.9) 10.4 (8.5-12.6) 13.1 (12.2-16.7) p=0.4624 
Albumin, g/L 37 (33-39) 32 (31-38) 37 (35-39) 37 (33-39) 36 (32-42) p=0.0754 
Pentosidine, nmol/L d 855 (609-1212) 650 (466-1735) 935 (691-1225) 752 (607-1393) 886 (696-984) p=0.9495 
8-OHdG, ng/mL d 0.18 (0.13-0.27) 0.14 (0.08-0.19) 0.21 (0.15-0.26) 0.16 (0.10-0.27) 0.30 (0.04-0.42) p=0.4616 
Calcification & bone markers             
CAC score, HU e 0 (0-111) 0 (0-0) 0 (0-90) 13 (1-171) 541 (28-1702) p=0.0154 
Media calcification, % f 1.8 (0.5-5.5) 0.2 (0-0.3) 1.2 (0.5-2.5) 4.9 (0.3-9.7) 25.3 (2.5-32.9) p<0.0001 
Calcium, mmol/L 2.3 (2.2-2.4) 2.2 (2.1-2.4) 2.4 (2.2-2.5) 2.3 (2.2-2.4) 2.2 (2.0-2.3) p=0.2136 
Phosphate, mmol/L 1.8 (1.5-2.1) 1.6 (1.4-2.1) 1.8 (1.4-2.2) 1.9 (1.5-2.1) 1.4 (0.9-1.5) p=0.2679 
Magnesium, mmol/L  0.9 (0.8-1.0) 0.8 (0.7-1.0) 0.8 (0.8-0.9) 0.9 (0.7-1.0) 0.9 (0.7-1.1) p=0.7395 
iPTH, ng/L 258 (190-400) 216 (181-286) 252 (190-384) 371 (228-583) 127 (85-210) p=0.1306 
25-OH D-vitamin, mmol/L g 39 (27-55) 33 (23-46) 37 (27-48) 51 (26-82) 39 (38-44) p=0.1777 
1,25-OH D-vitamin, pmol/L g 18 (13-27) 17 (12-19) 18 (13-28) 18 (12-29) 18 (7-49) p=0.6277 
FGF-23, pg/ml d 3353 (1114-31809) 5909 (1901-15150 3134 (453-33973) 4461 (1651-58853) 2184 (758-11994) p=0.4184 
Klotho, pg/ml h 395 (297-520) 509 (434-625) 349 (260-480) 391 (307-489) 409 (320-499) p=0.3608 
Alkaline phosphatase, U/L i 60.6 (49.6-89.2) 66.7 (47.2-126.1) 60.2 (50.3-82.7) 56.9 (47.9-78.1) 90.3 (47.0-113.1) p=0.5853 
Osteoprotegerin, pmol/L  5.9 (5.1-7.3) 5.3 (4.2-5.8) 6.1 (4.9-7.0) 5.8 (5.5-7.9) 9.3 (7.4-14.9) p=0.0049 
MID osteocalcin, ng/ml h 83.6 (37.3-184.9) 76.4 (27.5-148.3) 125.4 (41.9-220.1) 80.6 (48.6-204.3) 24.9 (7.0-147.6) p=0.4709 
GLA osteocalcin, ng/ml j 42.5 (22.3-66.0) 41.6 (26.7-62.4) 49.1 (22.4-66.8) 40.2 (27.8-74.7) 12.8 (8.5-27.3) p=0.3225 
GLU osteocalcin, ng/ml j 28.4 (8.0-56.5) 25.5 (15.7-77.6) 33.2 (9.4-56.8) 31.3 (6.9-75.4) 2.6 (1.5-33.0) p=0.5455 
Vascular expression (RQ)             
CDKN2B/p15INK4a  k 1.35 (0.81-1.87) 1.91 (0.78-2.49) 1.28 (0.97-1.74) 1.58 (0.81-2.00) 1.16 (0.36-2.26) p=0.3982 
CDKN2A/p16INK4a  1.04 (0.25-1.02) 0.94 (0.45-1.20) 1.02 (0.62-1.62) 1.12 (0.49-1.69) 2.60 (1.18-5.05) p=0.0108 
RUNX2 h 1.56 (1.02-2.81) 2.09 (1.00-3.04) 1.12 (1.00-2.01) 1.55 (1.31-2.34) 6.12 (3.89-6.13) p=0.0036 
Matrix Gla protein f 0.88 (0.61-1.30) 0.70 (0.45-1.00) 0.87 (0.58-1.25) 0.91 (0.62-1.40) 2.33 (0.70-3.65) p=0.0002 
Muscular expression (RQ)             





















































The expression of CDKN2A/p16INK4a did not differ 
between uremic arteries and skeletal muscle (median 
relative expression quantity 1.04 vs. 0.63 IU, p=0.79). 
No significant difference was observed in muscular 
CDKN2A/p16INK4a expression between patients with and 
without CVD (Table 1). The muscular expression of 
CDKN2A/p16INK4a correlated (Rho=0.30; p=0.02) with 
chronological age (Suppl. Fig. 2). A borderline 
significant (Rho=0.26; p=0.05) association was 















































of CDKN2A/p16INK4a (Suppl. Fig. 4). The muscular 
expression of CDKN2A/p16INK4a did not differ in 
patients with and without CVD nor between patients 
with CAC 0 vs. CAC >0 or the different calcification 
groups (Table 1).  
 
p16INK4a protein and SA-β-Gal expression  
 
Expression of p16INK4a in epigastric artery was absent, 
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increased in moderate VC and further exacerbated in 
severe VC (Fig. 4). Cells positive for p16INK4a were 
localized to the vascular media and in severe VC also in 
the intima and were more frequent (p<0.05) in areas 
with extensive calcification. The cellular localization of 
p16INK4a was mostly nuclear. The p16INK4a protein 
expression pattern mirrored the expression of 

















































cells was significantly (p<0.05) higher in severely 




We report that the arterial CDKN2A/p16INK4a (but not 
CDKN2B/p15INK4b) expression associate with CVD as 





















































for  moderate  VC  and  n=3  for  severe  VC).  The  number  of  positive  SA‐β‐Gal  positive  cells  increase  with  increased
calcification (C); no VC; n=2, mild VC; n=3, moderate VC; n=3 and severe VC; n=3. P‐values represent no vs. severe VC. 
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borated by increased number of p16INK4a and SA-β-Gal 
positive cells in severely calcified arteries (Fig. 4). 
Increased expression of p16INK4a (and the cellular 
senescence that follows) may be causally involved in 
the decline of cellular function of stem and progenitor 
cells [22] that are observed with organismal ageing. A 
recent study in mice implies a significant role of 
p16INK4a/β-GalpH6 positive macrophages and impaired 
immune system in aging [23]. Since vascular cell 
senescence contributes to breakdown of the blood-brain 
barrier [24] a consequence of increased vascular cell 
senescence may be higher cerebral concentrations of 
retained circulating cytokines, adipokines and uremic 
toxins. This may promote anorexia, cognitive 
dysfunction and depression; all common features in the 
uremic milieu [25, 26]. The senescence-associated 
secretory phenotype (SASP) - a key feature of cellular 
senescence - results in the secretion of pro-
inflammatory factors that poison the tissue in the 
proximity of the senescent cell. In accordance, we 
report a significant correlation between circulating IL-8 
and the arterial expression of CDKN2A/p16INK4a and 
higher IL-6 and OPG in severe VC (Table 1). Since 
senescent cells have been considered a target for anti-
aging therapies and removal of p16INK4a-positive cells in 
progeric mice led to an attenuation of the ageing 
phenotype [27], a functional involvement of p16INK4a in 
ageing-associated disorders is likely. The use of SASP 
modulators and senolytic drugs are intriguing prospect 
for the future treatment of uremic arteriosclerosis [28]. 
Indeed, a recent study in atherosclerotic mice show that 
chronic senolytic treatment improves established 
vascular dysfunction [29]. As we confirm that increased 
vascular senescence associates with low IGF-1 and 
testosterone levels [30, 31], the benefit of hormone 
replacement therapies needs consideration in this 
prematurely aged patient group. 
 
This the first report on the expression of p16INK4a in 
human uremic arterial tissue. Yamada et al. [32] showed 
increased arterial mRNA expression of Cdkn2a in rats 
with adenine-induced uraemia compared to control 
animals. Interestingly, they also demonstrated an 
increased arterial Runx2 mRNA expression, and both 
p16INK4a and Runx2 protein expression were detected in 
and around calcified areas of aortas from CKD rats, but 
not in normal rats [32]. We report higher arterial 
expression of RUNX2, MGP and CDKN2A/p16INK4a in 
ESRD patients with severe VC (Fig. 3). The higher 
MGP expression in arteries with severe media 
calcification may be regarded as an attempt to further 
prevent VC. Since VSMC apoptosis promote 
calcification [11], the relationship between the 
expression of the cell cycle inhibitor CDKN2A/p16INK4a 
and MGP is intriguing and requires further studies at the 
protein level.  
The underlying cause(s) of the increase in 
CDKN2A/p16INK4a expression were beyond the scope of 
this study. Although it has been reported that oxidative 
stress may be a culprit [33] we find no associations 
between CDKN2A/p16INK4a expression and circulating 
oxidative stress biomarkers. Prelamin A accumulation 
promotes calcification and ageing in VSMCs – an effect 
which appears to be mediated, at least in part, by p16 
protein. In addition, RUNX2 may be activated by 
prelamin A and DNA damage signalling [34, 35], 
further linking cellular stress, p16 activity and an 
osteogenic potential. Another possibility for increased 
p16INK4a expression in ESRD is impairment of immune 
system function [23]. It was recently reported that the 
uremic toxin p-cresylsulphate induces macrophage 
activation, which lead to a failure in adaptive immune 
response [36]. Since we report on a strong inverse 
association between high vascular CDKN2A/p16INK4a 
expression and low levels of carboxylated active 
osteocalcin (Fig. 2) it can be hypothesized that vitamin K 
deficiency and decreased carboxylation of Gla proteins 
promote vascular senescence. Indeed, the expression of 
OC decreases with older age [37] and low carboxylation 
of OC associates not only with decreased cellular 
secretion of OC but also less accumulation in tissue [38]. 
Our data support Idelevich et al. [39] who report that OC, 
by promoting the osteocondrogenic differentiation in 
VSMC, is an active player in the VC process. Since 
vitamin K deficiency is a common finding in CKD [40] 
and promotes low carboxylation of OC our findings 
support a role for vitamin K deficit in premature vascular 
aging [41]. The protective effect of vitamin K may not 
only occur via carboxylation of Gla rich proteins but also 
via inhibition of apoptosis, which reduces the 
transdifferentiation of VSMC to osteoblasts [38]. It is 
noteworthy that vitamin K deficiency is consistently 
linked to features of aging, such as sarcopenia, frailty, 
osteoporosis and insulin resistance [42]. Since Vitamin 
K2 promote progenitor cell differentiation [43] its effect 
on vascular senescence, p16 clearance and progenitor cell 
mobilisation deserve further studies.  
 
Some strengths and weaknesses of the present study 
deserve mentioning. An important strength is the access 
to highly biologically relevant methods and tissues. As 
opposed to being estimated by a surrogate marker of 
vascular stiffness the extent of VC was evaluated by 
three different methods. Moreover, gene expression data 
were obtained from the tissue directly affected by 
disease and we used von Kossa staining (the method of 
choice for detection of mineralisation). Finally, the 
presence of vascular senescence as estimated by arterial 
expression of CDKN2A/p16INK4a was mirrored by 
immunostaining of p16INK4a and SA-β-Gal (Fig. 4). 
Weak points of the study include the cross-sectional 
design. As many of the findings are correlational in 
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nature, conclusions on causation are impossible to infer 
and we cannot conclude on the pathogenic relationship 
between p16INK4a overexpression and VC. However, 
since we observed a significant correlation between 
CDKN2A/p16INK4a expression and media calcification 
after correction for age our data imply that p16INK4a is 
involved in the calcification process and not only a 
consequence of chronological aging. It should also be 
appreciated that patients in the study were a selected 
group of younger ESRD patients with a lower 
prevalence of CVD than the typical Caucasian dialysis 
patient (where a more aggravated vascular phenotype is 
expected). Thus, the results may not be applicable to 
older and sicker dialysis patients, nor dialysis patients 
of other ethnicities. Another limitation is the lack of 
data on vascular CDKN2A/p16INK4a and p16INK4a 
expression in age- and gender-matched non-uremic 
patients with arteriosclerosis. Future studies would 
benefit from a control group, as it would make it 
possible to determine the impact of the uremic milieu 
on the degree of cellular senescence and 
CDKN2A/p16INK4a and p16INK4a expression. It should 
also be pointed out that VC might vary depending on 
arterial type and location along any specific artery. 
However, we reported a close relation between 
epigastric artery medial calcification and extent of 
coronary artery calcification [44]. Finally, since RNA 
was prepared from a homogenised arterial sample, this 
precludes any knowledge on how the expression varied 
between different cell types. Still, the multiple 
associations of CDKN2A/p16INK4a with different 
markers of VC increase the strength of our findings. 
 
In summary, we demonstrate that in the uremic milieu, 
increased arterial expression of CDKN2A/p16INK4a 
associated with vascular progeria, independently of 
chronological age. These findings are supported by the 
increased number of p16INK4a and SA-β-Gal positive 
cell in arteries with severe VC. Further studies should 
evaluate if impaired Vitamin K mediated carboxylation 
contribute to premature vascular senescence. 
 




Adult patients undergoing living donor kidney 
transplantation (RTx) at the Dept. of Transplantation 
Surgery at the Karolinska University Hospital were 
invited to participate in the study. All participants 
provided written informed consent and the Regional 
Ethical Review Board in Stockholm approved the study. 
Basic patient characteristics are outlined in Table 1. 
Whereas 39 patients had undergone dialysis treatment 
prior to RTx (median dialysis vintage 0.3 years) 22 
patients underwent pre-emptive RTx. Eighteen of the 
individuals that were treated with dialysis had received 
haemodialysis (HD), 20 had received peritoneal dialysis 
(PD) and one had initially received PD but switched to 
HD. The median age was 45 years and 69% were males. 
Smoking status (no, former and current smoker) and 
degree of physical activity (high, moderate and low) 
were recorded. The most common causes of CKD were 
chronic glomerulonephritis (n=27), polycystic kidney 
disease (n=10), interstitial nephritis (n=3) and other (or 
unknown) causes (n=21). The median systolic and 
diastolic blood pressures were 142 (IQR 129-152) and 
86 (IQR 74-93) mmHg, respectively. The most 
commonly used medications were erythropoietin-
stimulating agents (84%), non-calcium-based phosphate 
binders (75%), calcium-based phosphate binders (4%) 
and loop-diuretics (62%). Commonly used anti-
hypertensive treatments were β-blocking agents (52%) 
and ACE-i/ARBs (72%); 30% of the patients were on 
statins. One patient was on warfarin. In this group of 
younger patients only five had clinical signs of 
cerebrovascular, cardiovascular, and/or peripheral 
vascular disease (grouped as CVD). Three had clinical 
signs of ischemic heart disease and two had peripheral 




Within 20 minutes after skin incision, skeletal muscle 
and an artery (1-2 cm) were collected by sharp 
dissection. Muscle samples were taken from the 
external or internal oblique muscle or from the 
transverse abdominal muscle, and artery samples were 
obtained from the inferior epigastric artery. Samples 
were immediately placed in AllProtect Tissue Reagent 
(Qiagen, Hilden, Germany), snap-frozen in isopentane 
and subsequently stored at -70 °C, or fixed in 4% 
phosphate buffered formalin. Formalin-fixed material 
from the epigastric arteries was embedded in paraffin. 
One or two separate tissue sections (1-2 µm thick) were 
stained with hematoxylin and eosin and van Kossa, 
respectively, and were evaluated by two experienced 
pathologists (AW and MS). The degree of medial 
calcification was semi-quantified on the van Kossa 
stained sections and graded 0-3, where 0 indicated no 
calcification and 3 the highest degree of calcification 
[44]. Degree of calcification was also assessed as a 
continuous variable by semi-automated quantification 
as previously described [44]. The correlation 
(p<0.0001) between semi-quantitative histological 
assessment and semi-automated quantification of media 




Blood samples were obtained in a fasting state in the 
morning the day before the surgical procedure, and 
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stored in -80 °C. Interleukin (IL)-6, IL-8, TNF, IGF-1 
and testosterone were analysed by immunometric assays 
on an Immulite 1000 Analyzer (Siemens Healthcare 
Diagnostics, Los Angeles, CA, USA) according to the 
instructions of the manufacturer. Plasma pentosidine 
was analysed by reverse-phase high performance liquid 
chromatography (HPLC). The following biomarkers 
were analysed with ELISA technique; 8-OHdG (Japan 
Institute for the Control of Aging, Shizuoka, Japan), 
osteoprotegerin (OGP) (Quidel Corporation, San Diego, 
CA, USA), human soluble α-Klotho (Immuno-
Biological Laboratories Co., Ltd, Fujioka-shi, Japan), 
C-terminal FGF-23 (Immutopics Inc, San Clemente, 
CA, USA), Human N-MID Osteocalcin ELISA (IDS 
Nordic a/s, Herlev, Denmark), GLA-OC) and GLU-OC  
(Takara Bio Inc, Kusatsu, Japan). N-MID OC ELISA 
measuring total OC is more stable and reproducible than 
assays measuring intact OC only. Analyses of hsCRP, 
intact parathyroid hormone (iPTH), plasma cholesterol, 
triglycerides, HDL-cholesterol, creatinine, albumin, 
calcium, magnesium, phosphate, alkaline phosphatase 
(ALP), 25(OH) and 1,25(OH) D-vitamin were 
performed with validated routine methods at the 
accredited Clinical Chemical Laboratory Lab at the 




All cardiac computed tomography (CT) scans were 
performed using a 64-channel detector scanner 
(LightSpeed VCT; General Electric (GE) Healthcare, 
Milwaukee, WI, USA) in cine mode. Scans were ECG-
gated and a standard non-contrast protocol was used 
with a tube voltage of 100 kV, tube current of 200 mA, 
350 ms rotation time, 2.5 mm slice thickness and 
displayed field of 25 cm. Calcium deposits in the 
coronary arteries were identified by a radiologist with 
Level 2 competence and extensive experience of cardiac 
CT interpretation. Data were subsequently processed 
and analysed using an Advantage Workstation (GE 
Healthcare). Smartscore 4.0 (GE Healthcare) was used 
to assess CAC scores. Calcified plaques were 
considered to be present if values exceeded the standard 
threshold of 130 Hounsfield units. The CAC scores 
were expressed in Hounsfield units (HU) as previously 
described in detail [45]. Total CAC score was defined 
as the sum of the CAC scores in the left main artery, the 
left anterior descending artery, the left circumflex artery 
and the right coronary artery.  
 
RNA preparation and gene expression analysis 
 
TRIzol® Reagent (Ambion, Life Technologies, 
Carlsbad, USA) was used to prepare total RNA from 
artery and muscle biopsies according to the 
manufacturer’s recommendation. RNA concentration 
was determined using a NanoDrop ND-1000 
spectrophotometer (NanoDrop products, Wilmington, 
USA) and RNA integrity was evaluated by an Agilent 
2100 BioAnalyzer (Agilent Technologies Inc., Santa 
Clara, USA). For further analysis only samples with 
RIN>5.5 were used. Reverse transcription reaction was 
performed using random hexamers and SuperScriptIII® 
kit as per manufacturer’s instructions (Invitrogen, Life 
Technologies, Carlsbad, USA). QPCR was performed 
using individual TaqMan® gene expression assays 
specific to CDKN2A/p16INK4a (#Hs00923894_m1), 
CDKN2B/p15 (# Hs00793225_m1) and HPRT1 (# 
Hs02800695_m1), as a reference gene, using 7500 Fast 
Real Time PCR (Applied Biosystems, Life Technologies, 
Carlsbad, USA). Gingell-Littlejohn et al. [20] previously 
published the primer sequences. Expression of 
MGP(Hs00969490_m1) and RUNX2 (Hs00231692_m1) 
was analysed using a TaqMan Low Density Array on a 
QuantStudioTM 7 Flex Real-Time PCR system (Life 
Technologies, Carlsbad, CA, USA) according to the 
manufacturer’s instructions and 30-1000 ng of cDNA 
from epigastric artery was added to the array. 
Amplification profiles for each sample and target were 
analysed individually and profiles with Ct above 35, bad 
passive reference signal, noise spikes and high noise 
were removed from further analyses. The data were 
analysed using ExpressionSuite®Software v1.0.4 
(Applied Biosystems, Life Technologies, Carlsbad, CA, 
USA), and the 2-ΔΔCT formula was used to transform 




Immunohistochemistry of p16INK4a was performed on 
paraffin-embedded sections of epigastric arteries from 
11 subjects. Samples were divided according to amount 
of VC; no VC (n=2), minor VC (n=3), moderate VC 
(n=3) and severe VC (n=3). Anti-CDKN2A/p16INK4a 
polyclonal antibody was used (host species: rabbit, 
Antibody Registry ID: AB_306176, product number 
ab7962 Abcam, Cambridge, United Kingdom) and the 
analysis was performed using an established automated 
method at Dept. of Pathology, Karolinska University 
Hospital, Sweden. Staining and counterstaining were 
performed using diaminobenzidine (DAB) and 
hematoxylin, respectively. A section lacking primary 
antibody was used as a negative control. The score for 
p16INK4a positivity was calculated as the percentage of 
p16INK4a positive cells out of the total number of cells in 
the media and intima layers in one arterial section.  
 
Senescence associated β-galactosidase (SA-β-Gal) 
staining 
 
SA-β-Gal staining was performed using Senescence 
Cell Histochemical Staining kit (Sigma-Aldrich, UK) 
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with sections being fixed for 1 min in room temperature, 
washed three times in PBS and immersed in SA-β-Gal 
staining solution overnight in 37°C. Tissue sections were 
counterstained with eosin and viewed by bright-field 
microscopy. The percentage of senescent cells (SA-β-Gal 
positive cells) and the total number of cells was counted 
for each section in the six independent fields. Each group 




All continuous variables were expressed as median 
(interquartile range) and nominal variables as 
percentage, unless otherwise indicated. Statistical 
significance was set at the level of p<0.05. Comparisons 
between two groups were assessed with Wilcoxon rank 
sum test or χ2 test, as appropriate. Differences between 
the four groups were analysed by ANOVA. Spearman’s 
rank correlation (ρ) was used to determine correlations 
between two continuous variables. Multivariate analysis 
was performed using general linear model (GLM). 
Statistical analyses were performed using statistical 
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Suppl. Figure 2. Correlation between  chronological age and  the arterial  (A) and muscular  (B)
expression of CDKN2A/p16INK4a.  











Suppl.  Figure  4.  Correlation  between  the  arterial  and  muscular  expression of
CDKN2A/p16INK4a in end‐stage renal disease. 
Suppl. Figure 3. Correlation between arterial expression levels of CDKN2A/p16INK4a
and % calcified media (by semi‐automated picture analysis). Following the correction
for age the association achieved statistical significance (p=0.0003).  
